> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Clears Legend Biotech's LB2501, A CAR-T Therapy Built Inside The Body, For U.S. Testing
- URL: https://www.bullished.co/fda-clears-legend-biotechs-lb2501-a-car-t-therapy-built-inside-the-body-for-u-s-testing-b042dbf2/
- Published: 2026-10-15T12:06:44.000Z
- Updated: 2026-10-15T12:06:44.000Z
- Description: Legend Biotech plans a U.S. Phase 1/2 study of LB2501 in relapsed or refractory B-cell cancers, without lymphodepleting chemotherapy.
- Author: Matteo Parrino
- Tags: SEC Filings, LEGN, Industry: Healthcare

The U.S. Food and Drug Administration has [cleared the investigational new drug application](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006646/exh%5F991.htm?ref=bullished.co) for LB2501, Legend Biotech said Thursday in a release furnished to the SEC on Form 6-K. The therapy is designed to make CAR-T cells, a type of engineered immune cell, inside the patient rather than in a lab.

## What the release says

LB2501 is an off-the-shelf, single-infusion therapy that generates CAR-T cells carrying a receptor aimed at two targets, CD19 and CD20\. The company calls it the first known dual-targeting in vivo CAR-T therapy to receive FDA IND clearance, a description it applies to itself.

A planned U.S. Phase 1/2 study will assess safety, tolerability, pharmacokinetics and preliminary efficacy in relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin lymphoma. The release says the therapy is being evaluated without lymphodepleting chemotherapy.

LB2501 is already in an ongoing Phase 1, open-label study in China in patients with relapsed or refractory B-cell malignancies, the release says. That study is assessing safety, tolerability and preliminary efficacy.

The therapy is built on Legend's proprietary TaVec platform and uses an engineered, replication-incompetent lentiviral vector designed to selectively transduce T cells. Once transduced, the cells produce a receptor that targets both CD19 and CD20\. The company says the dual approach is intended to help address antigen escape and other possible routes of treatment resistance.

## What it changes

Making the cells in the body could potentially avoid several manufacturing steps required for conventional autologous CAR-T therapies, the company says. Autologous means made from the patient's own cells.

Chief Executive Officer Ingrid Zhang said: "We believe in vivo CAR-T represents the [next frontier of cell therapy.](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006646/exh%5F991.htm?ref=bullished.co)" She called the clearance "an important step" for LB2501 and the broader in vivo platform.

The release says B-cell non-Hodgkin lymphoma accounts for 90% of all malignant lymphomas, and that patients with relapsed or refractory disease, particularly after multiple lines of therapy, often face limited options.

Market data showed Legend's U.S.-listed shares closed at $19.04 on Wednesday, up 6.49% from the prior session, before the announcement. Its market value was $3.7 billion.

The U.S. trial is still planned; the release gives no start date, and the China study remains ongoing.

### Sources

- [Form 6-K — IND clearance supports planned U.S. Phase 1/2 study and advances Legend Biotech’s in vivo cell engineering platform](https://www.sec.gov/Archives/edgar/data/1801198/000117184326006646/exh%5F991.htm?ref=bullished.co) — SEC EDGAR